Streetbeat News

Stock Prices

WDAY

A comparative study of Workday (NASDAQ:WDAY) and its competitors in the Software industry reveals Workday's high PE ratio, suggesting overvaluation, but lower PB and PS ratios indicate potential undervaluation. Despite lower ROE, EBITDA, and gross profit compared to industry averages, Workday's revenue growth outperforms peers. The analysis also highlights Workday's strong financial position with a lower debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:01 pm

SSRM

SSR Mining (NASDAQ:SSRM) is scheduled to release its quarterly earnings report on February 27, 2024, with analysts expecting an EPS of $0.33. The company's past earnings performance shows a mixed impact on its stock price, with a notable 1.79% drop after missing EPS estimates last quarter. SSR Mining's stock has declined 66.41% over the last 52 weeks, trading at $4.63 as of February 23.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:01 pm

JLL

Jones Lang LaSalle (NYSE:JLL) is scheduled to release its quarterly earnings report on February 27, 2024, with an expected EPS of $3.74. Historical data shows mixed EPS performance but generally positive stock price reactions post-earnings. Shares have increased by 5.45% over the last 52 weeks, indicating a positive trend for long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

MRK

Merck & Co (NYSE:MRK) has seen significant options trading activity, with a bearish sentiment prevailing among big-money investors. Benzinga's options scanner revealed 14 unusual trades, with a split sentiment of 28% bullish and 71% bearish. The trades include 8 puts and 6 calls, indicating a price target range of $110.0 to $145.0. Recent analyst ratings have varied, with an average target price of $139.4. The stock is currently trading at $129.13, down by -0.25%, and may be considered overbought.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

CCCC

C4 Therapeutics (NASDAQ:CCCC) has received mixed analyst ratings over the last three months, with a shift towards a more neutral stance in the last 30 days. Analysts have updated their price targets, indicating a significant increase in the average target to $9.75, up 95% from the previous $5.00. The company has shown a strong revenue growth rate of 63.93% as of September 30, 2023, but trails behind its peers in the Health Care sector. Despite a high net margin of -244.19% and impressive ROE and ROA figures, C4 Therapeutics's market capitalization remains below the industry average.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

KKR

KKR & Co (NYSE:KKR) is analyzed against its Capital Markets industry peers, showing potential undervaluation based on its PE ratio but overvaluation on PB and PS ratios. With a higher ROE, EBITDA, gross profit, and revenue growth compared to industry averages, KKR demonstrates strong operational efficiency and growth prospects. The article also compares financial metrics like debt-to-equity ratio, positioning KKR in the middle among its top 4 peers.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

NEM

Newmont (NYSE:NEM) has seen a surge in options activity, with 58% of traders bullish and 42% bearish. Notable trades include both puts and calls, with a price target range from $25.0 to $55.0. Newmont, the world's largest gold miner, recently acquired Newcrest, boosting its production and reserves. Currently, NEM's stock is down by -2.14% at $30.61, with analysts from BMO Capital and RBC Capital giving price targets of $56 and $40, respectively.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

BLDR

Builders FirstSource (NYSE:BLDR) has significantly outperformed the market with an annualized return of 68.25% over the past 5 years, turning a $1000 investment into $13,579.33. The company now has a market capitalization of $23.29 billion.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

REGN

Over the past 20 years, Regeneron Pharmaceuticals (NASDAQ:REGN) has produced an average annual return of 23.18%, outperforming the market by 15.52%. A $100 investment in REGN 20 years ago would be worth $6,532.07 today. The company's current market capitalization stands at $107.54 billion.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm

EGLE

Eagle Bulk Shipping (NYSE:EGLE) has been evaluated by 4 analysts over the last three months, with all maintaining an indifferent stance. The average 12-month price target for EGLE has been adjusted to $53.55, down from $63.00, indicating a 15.0% decrease. The company's financial performance shows challenges in revenue growth, profitability, and debt management, with a notable revenue decline of -55.42% over the past 3 months and below-average net margin and ROE.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:00 pm